Freya Biosciences ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
Estimate generation in progress, please wait...
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  0.0% 4.8% 6.2% 19.0% 7.7%  
Credit score (0-100)  0 44 37 6 31  
Credit rating  N/A BBB BBB B BB  
Credit limit (kDKK)  0.0 0.0 0.0 -0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  0.0 -577 -11,236 -2,231 -5,366  
EBITDA  0.0 -2,103 -22,636 -39,181 -87,196  
EBIT  0.0 -2,118 -22,759 -39,304 -87,287  
Pre-tax profit (PTP)  0.0 -2,152.7 -22,889.0 -39,108.0 -86,596.0  
Net earnings  0.0 -1,894.7 -20,406.0 -32,157.0 -81,096.0  
Pre-tax profit without non-rec. items  0.0 -2,153 -22,889 -39,108 -86,596  

 
See the entire income statement

Balance sheet (kDKK) 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  0.0 437 385 262 171  
Shareholders equity total  0.0 16,761 28,412 -3,745 75,005  
Interest-bearing liabilities  0.0 0.0 0.0 13,014 57.0  
Balance sheet total (assets)  0.0 17,194 32,367 16,376 81,766  

Net Debt  0.0 -12,913 -24,465 7,899 -74,046  
 
See the entire balance sheet

Volume 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  0.0 -577 -11,236 -2,231 -5,366  
Gross profit growth  0.0% 0.0% -1,848.0% 80.1% -140.5%  
Employees  0 0 0 8 14  
Employee growth %  0.0% 0.0% 0.0% 0.0% 75.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0 17,194 32,367 16,376 81,766  
Balance sheet change%  0.0% 0.0% 88.2% -49.4% 399.3%  
Added value  0.0 -2,102.6 -22,636.0 -39,181.0 -87,196.0  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 422 -175 -246 -182  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  0.0 -1.0 -2.0 -3.0 -4.0  

Profitability 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  0.0% 367.2% 202.6% 1,761.7% 1,626.7%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  0.0% -12.3% -91.8% -145.0% -169.7%  
ROI %  0.0% -12.6% -100.7% -183.7% -196.3%  
ROE %  0.0% -11.3% -90.3% -143.6% -177.5%  

Solidity 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  0.0% 97.5% 87.8% -18.6% 91.7%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.0% 614.1% 108.1% -20.2% 84.9%  
Gearing %  0.0% 0.0% 0.0% -347.5% 0.1%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 16.1% 2.3%  

Liquidity 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  0.0 38.4 8.1 2.2 12.0  
Current Ratio  0.0 38.4 8.1 2.2 12.0  
Cash and cash equivalent  0.0 12,913.0 24,465.0 5,115.0 74,103.0  

Capital use efficiency 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 180.5 97.7 931.4 360.1  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  0.0 16,217.8 27,892.0 8,872.0 74,699.0  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 -4,898 -6,228  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 -4,898 -6,228  
EBIT / employee  0 0 0 -4,913 -6,235  
Net earnings / employee  0 0 0 -4,020 -5,793